| August 2020 |
| 31 Aug |
Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes |
 |
| July 2020 |
| 31 July |
Tata Capital Growth Fund to Invest ~USD 30 million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85% Deal Values Biocon Biologics at USD 3.5 Billion. |
|
| 23 July |
Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr |
|
| 21 July |
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins |
|
| 13 July |
Biocon Presented Insights into Clinical Study That Enabled DCGI Approval of Itolizumab for COVID-19 |
|
| 11 July |
Biocon's Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients |
|
| June 2020 |
| 22 June |
Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets |
|
| 12 June |
Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection) |
|
| 01 June |
Kiran Mazumdar-Shaw Wins EY World Entrepreneur of the Year™ 2020 Award |
|
| 01 June |
Biocon's* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi's Four Device Patents for Lantus® SoloSTAR® |
|
| May 2020 |
| 27 May |
Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients |
|
| 19 May |
Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab |
|
| 14 May |
Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr |
|
| 12 May |
Company Statement: Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification |
|
| 08 May |
Company Statement: Biocon Receives EIR for Small Molecules API Manufacturing Facility for Pre -Approval and GMP U.S. FDA Inspection |
|
| April 2020 |
| 27 Apr |
Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Canada |
|
| 27 Apr |
Press Note: Kiran Mazumdar-Shaw Recognized among World's Top 20 Inspirational Leaders in Biopharmaceuticals in The Medicine Maker 'Power List 2020' |
|
| 16 Apr |
Company Statement: Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed |
|
| 14 Apr |
Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia |
|
| 01 Apr |
Company Statement: Biocon's Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed |
|
| March 2020 |
| 27 Mar |
Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers |
|
| 20 Mar |
Company Statement: Biocon Receives EIR for Small Molecules API Manufacturing Facility for Post - Approval and GMP U.S. FDA Inspection |
|
| 11 Mar |
Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S. |
|
| 09 Mar |
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review |
|
| February 2020 |
| 27 Feb |
Company Statement: Biocon's Small Molecules API Manufacturing Facility Completes Post-Approval and GMP U.S. FDA Inspection |
|
| 22 Feb |
Company Statement: Biocon's Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection |
|
| 20 Feb |
Kiran Mazumdar-Shaw Named EY Entrepreneur of the Year India 2019 |
|
| January 2020 |
| 27 Jan |
Company Statement: Biocon's Small Molecules API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA inspection |
|
| 23 Jan |
Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6% |
|
| 20 Jan |
Company Statement: Biocon's Oral Solid Dosage Manufacturing Facility Completes Pre-Approval U.S. FDA lnspection with Zero Observations |
|
| 19 Jan |
Kiran Mazumdar-Shaw Honoured with Order of Australia, Australia's Highest Civilian Honour |
|
| 06 Jan |
True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake |
|
| 06 Jan |
Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer |
|
